Shenzhen YHLO Biotech Co., Ltd. (688575.SS)

CNY 16.47

(0.37%)

Market Cap (In CNY)

9.39 Billion

Revenue (In CNY)

2.03 Billion

Net Income (In CNY)

355.01 Million

Avg. Volume

2.68 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
16.03-28.27
PE
-
EPS
-
Beta Value
0.662
ISIN
CNE100005204
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Mr. Yongbo Song
Employee Count
-
Website
https://www.szyhlo.com
Ipo Date
2021-05-17
Details
Shenzhen YHLO Biotech Co., Ltd. engages in developing, manufacturing, and distributing in-vitro diagnostic instruments and reagents in China. It offers clinical solutions for autoimmune, reproductive health, infectious, and other diseases; CLIA test panels, chemiluminescence immunoassay analyzers, and integration systems for immunoassay; ELISA test panels and immune analyzers; LIA test panels, blot analyzers, and line immunoassays; POCT test panels and immunofluorescence readers; ESR Analyzers; and COVID-19 detection kits. The company also exports its COVID-19 detection kits to various countries, including Germany, France, Italy, Denmark, Sweden, etc. Shenzhen YHLO Biotech Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.